Figure 2From: Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)Reduction in inflammatory markers in response to a single dose of canakinumab.Back to article page